We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.71%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$810M
AUM Growth
-$260M
Cap. Flow
-$189M
Cap. Flow %
-23.28%
Top 10 Hldgs %
32%
Holding
105
New
11
Increased
30
Reduced
42
Closed
19

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$17.2M
2
VEEV icon
Veeva Systems
VEEV
+$16.8M
3
BSX icon
Boston Scientific
BSX
+$15.5M
4
ABT icon
Abbott
ABT
+$12.6M
5
WAY
Waystar Holding Corp
WAY
+$9.09M

Top Sells

Rank Stock Value
1
COO icon
Cooper Companies
COO
+$22M
2
VERA icon
Vera Therapeutics
VERA
+$21.3M
3
MDT icon
Medtronic
MDT
+$19.7M
4
DHR icon
Danaher
DHR
+$17.2M
5
ALGN icon
Align Technology
ALGN
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$29.5B
$11.4M 1.41%
34,465
-11,210
-25% -$3.81M
RPRX icon
27
Royalty Pharma
RPRX
$25.3B
$11.2M 1.38%
233,000
+26,500
+13% +$1.16M
AXSM icon
28
Axsome Therapeutics
AXSM
$10.9B
$10.8M 1.33%
63,800
-51,000
-44% -$8.81M
NTRA icon
29
Natera
NTRA
$38.7B
$10.3M 1.27%
51,600
+11,100
+27% +$2.39M
THC icon
30
Tenet Healthcare
THC
$20.1B
$10.2M 1.26%
54,000
-22,504
-29% -$4.74M
ADPT icon
31
Adaptive Biotechnologies
ADPT
$3.68B
$9.99M 1.23%
720,000
+115,000
+19% +$1.83M
LIVN icon
32
LivaNova
LIVN
$4.53B
$9.85M 1.22%
155,000
-35,000
-18% -$2.26M
ELV icon
33
Elevance Health
ELV
$83B
$9.46M 1.17%
32,300
+17,300
+115% +$5.69M
ARWR icon
34
Arrowhead Research
ARWR
$12.1B
$9.06M 1.12%
144,500
– –
GKOS icon
35
Glaukos
GKOS
$10.1B
$9.04M 1.12%
84,000
-126,000
-60% -$14.2M
IQV icon
36
IQVIA
IQV
$38.4B
$9.04M 1.12%
53,000
+26,500
+100% +$5.17M
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.7B
$8.86M 1.09%
379,250
-107,750
-22% -$2.34M
MIRM icon
38
Mirum Pharmaceuticals
MIRM
$6.38B
$8.55M 1.06%
92,605
-13,650
-13% -$1.28M
IDYA icon
39
IDEAYA Biosciences
IDYA
$3.41B
$8.51M 1.05%
255,500
+5,500
+2% +$185K
PNTG icon
40
Pennant Group
PNTG
$1.4B
$8.39M 1.04%
275,399
-81,947
-23% -$2.53M
NUVL
41
DELISTED
Nuvalent
NUVL
$8.32M 1.03%
81,200
-82,150
-50% -$8.37M
WAY
42
Waystar Holding Corp
WAY
$4.35B
$8.26M 1.02%
+342,566
New +$9.09M
AVR
43
Anteris Technologies
AVR
$806M
$7.98M 0.99%
1,438,625
+200,000
+16% +$1.15M
MDT icon
44
Medtronic
MDT
$111B
$7.8M 0.96%
90,000
-206,000
-70% -$19.7M
OSCR icon
45
Oscar Health
OSCR
$9.27B
$7.57M 0.93%
660,000
+400,000
+154% +$5.63M
IOVA icon
46
Iovance Biotherapeutics
IOVA
$1.95B
$7.21M 0.89%
2,055,327
+460,000
+29% +$1.47M
MLYS icon
47
Mineralys Therapeutics
MLYS
$2.27B
$7.13M 0.88%
263,071
+120,500
+85% +$3.53M
IONS icon
48
Ionis Pharmaceuticals
IONS
$9.06B
$6.98M 0.86%
92,900
-65,600
-41% -$5.18M
DNTH icon
49
Dianthus Therapeutics
DNTH
$5.8B
$6.85M 0.85%
81,627
-17,000
-17% -$984K
BBIO icon
50
BridgeBio Pharma
BBIO
$15.7B
$6.73M 0.83%
90,600
+9,000
+11% +$652K
1
2
3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rhenman & Partners Asset Management held 105 positions worth $810M, down 24% from $1.07B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $189M in Q1 2026, closing 19 positions and reducing 42 holdings. Its most notable exit was Vera Therapeutics, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Stryker worth $15.7M.

  • Rhenman & Partners Asset Management's largest Q1 2026 buy was Stryker: 47,800 shares worth $15.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q1 2026, an estimated $15.5M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2026 reduction was Cooper Companies, cutting an estimated $22M.
  • Rhenman & Partners Asset Management fully exited Vera Therapeutics in Q1 2026, selling an estimated $21.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $810M portfolio in Q1 2026.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 19 in Q1 2026.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $810M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.